Spiegelberg, Jasmin http://orcid.org/0000-0003-4393-0577
Funding for this research was provided by:
Medical University of Graz
Article History
Received: 5 August 2023
Accepted: 19 September 2023
First Online: 7 November 2023
Conflict of interest
: J. Spiegelberg makes the following statements: advisory boards: Astellas, Ipsen Pharma. Lecture activity: BMS, AstraZeneca.